Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive

SGIActive

Will SGI affirm or raise the Mattress Firm $225M run-rate synergy target at FY2026 year-end earnings?

Resolves February 28, 2027(237d)

IG: 0.48

Current Prediction

72%

Likely Yes

Model Agreement97%

Predictions9 runs

Last UpdatedApril 22, 2026

Why This Question Matters

The $225M raised synergy target is management's credibility benchmark. Affirmation or raise at FY2026 year-end validates that Leggett execution concentration did not disrupt Mattress Firm integration. A guide-down would confirm the primary risk identified by Consolidation Calibrator — stacked deal execution. This is a year-end 2026 readthrough on whether the consolidator track record extends through the current stack.

CAPITAL_DEPLOYMENTGOVERNANCE_ALIGNMENT

Prediction Distribution

0%25%50%75%100%

opus

sonnet

haiku

Range: 70% – 75%Aggregate: 72%

Individual Predictions(9 runs)

opusRun 1

72%

Base rate: acquisitions with synergy capture ahead of schedule in year 1 typically hold/raise the target in year 2 at ~75-85%. SGI already raised from $200M to $225M, which is evidence of conservative initial target. $80M captured in 2025 vs original $200M target on schedule; now tracking toward $225M. Management's cadence of quarterly synergy updates makes silence unlikely at FY2026 year-end earnings. Discount for stacked Leggett execution: -5pp. Discount for industry weakness affecting sales-synergy portion: -5pp. Net: 0.72.

75-85% base rate for ahead-of-schedule acquisitions to hold/raise in year 2Quarterly update cadence minimizes silence riskStacked Leggett execution and sales-synergy cyclicality discounts

opusRun 2

75%

Management track record: prior consolidator deals (Sealy 2013, Tempur Sealy 2022) saw synergy targets held or raised in subsequent years. The $225M raise is itself a commitment. Q4 2026 call (Feb 2027) is ~10 months away; by then 2/3 of the synergy journey will be complete. Strong structural reasons to affirm: (a) management incentives, (b) 2028 EPS target depends on it, (c) investor relations committed cadence. Primary downside: Leggett integration distracting or specific cost-synergy projects slipping. Probability 0.75.

Prior deal synergy-target history supports affirmationManagement has structural incentives to affirmLeggett distraction primary downside

opusRun 3

70%

Key risk underweighted: sales synergy portion ($100M run-rate, $60M delivered 2025 + $40M wraparound 2026) depends on category demand and continued balance-of-share gains. If industry deteriorates further, sales synergy could underperform. Cost synergy ($125M) is more controllable. If cost synergy is on track but sales synergy underperforms, management might affirm total target via pro-forma adjustments or might quietly revise down. Silence-as-NO criteria is strict. Land at 0.70.

Sales-synergy portion cyclical-dependent; industry risk realCost synergy more controllableStrict silence-as-NO criteria

sonnetRun 1

72%

Three elements support YES: (a) ahead-of-schedule capture in 2025, (b) management consistent update cadence, (c) structural incentives to affirm. Two elements against: (a) Leggett execution concentration, (b) industry cyclical risk for sales-synergy portion. Net 0.72.

Ahead-of-schedule capture in year 1Management structural incentives to affirmLeggett + cyclical risk offsets

sonnetRun 2

70%

Slightly more cautious: the 10-month horizon introduces path-dependency. If Q2 or Q3 2026 shows Mattress Firm L-f-L weakness, sales synergy delivery is at risk. Cost synergy remains solid. Management might affirm even with mix shift (cost synergy higher, sales lower). Probability 0.70.

Path dependency over 10-month horizonCost synergy more secure than sales synergyManagement could mix-shift within total

sonnetRun 3

73%

Weight of evidence favors affirmation: $225M was itself raised; 2025 delivery on pace; 2028 EPS target dependency creates strong incentive to affirm. Cost synergy initiatives ($55M 2026 + $50M 2027 incremental) are largely distribution/procurement, which are execution-controllable. Land at 0.73.

Target was itself raised = conservative starting point2028 EPS target creates strong affirmation incentiveCost synergy is execution-controllable

haikuRun 1

72%

Base rate ~75% for hold/raise in year 2 when year 1 delivery is ahead. Discount for Leggett distraction and industry risk. Land at 0.72.

75% base rate for hold/raise after year 1 aheadLeggett distraction discountIndustry risk discount

haikuRun 2

70%

Moderate lean YES. Management has strong reasons to affirm; primary risk is silence-at-year-end in favor of more granular guidance framework. 0.70.

Strong management incentives to affirmSilence-as-NO riskModerate lean YES

haikuRun 3

74%

Track record of raising (Sealy, Tempur Sealy precedent) plus 2025 pace on $225M target supports affirmation. Leggett risk moderate. 0.74.

Precedent deals show affirmation pattern2025 pace supports $225M run-rateLeggett risk moderate

Resolution Criteria

Resolves YES if SGI Q4 2026 earnings release or call (expected February 2027) explicitly affirms or raises the $225M Mattress Firm run-rate synergy target (cost + sales combined). Resolves NO if the target is explicitly reduced, or if the Q4 2026 earnings release omits a synergy target update (silence treated as de-facto reduction given management's prior cadence of explicit updates).

Resolution Source

SGI Q4 2026 earnings release, investor call transcript, or 10-K filing

Source Trigger

Mattress Firm synergy realization is running ahead of schedule — $225M raised target, $80M 2025 actual

consolidation-calibratorCAPITAL_DEPLOYMENTHIGH

View SGI Analysis

Full multi-lens equity analysis